- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Polysorbate.
Displaying page 1 of 1.
EudraCT Number: 2006-001685-16 | Sponsor Protocol Number: 6096A1-009 | Start Date*: 2015-04-09 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmceuticals Inc. | ||
Full Title: A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healt... | ||
Medical condition: Healthy infants | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-005890-37 | Sponsor Protocol Number: K201-I/280301BS | Start Date*: 2008-12-30 | |||||||||||
Sponsor Name:Moberg Derma AB | |||||||||||||
Full Title: Assessment of the effects on barrier impairment, clinical features and bacterial colonization of topical formulations in patients with atopic eczema; a phase IIa, single-center, randomized, observe... | |||||||||||||
Medical condition: To assess the barrier impairment, clinical skin condition and bacterial colonization in patients with atopic eczema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005090-26 | Sponsor Protocol Number: Kleb4V01 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:LimmaTech Biologics AG | |||||||||||||
Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study. | |||||||||||||
Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003430-42 | Sponsor Protocol Number: MKC-253-002 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:MannKind Corporation | |||||||||||||
Full Title: A Phase 1, Repeated Single-Dose, Double Blind, Randomized Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002094-23 | Sponsor Protocol Number: EORTC 30021 | Start Date*: 2004-12-20 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC | |||||||||||||
Medical condition: Patients with Hormone- Refractory Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002272-14 | Sponsor Protocol Number: CDX110-07 | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:CELLDEX THERAPEUTICS | |||||||||||||
Full Title: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glio... | |||||||||||||
Medical condition: Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004150-32 | Sponsor Protocol Number: A8851008 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Pfizer, Spain | |||||||||||||
Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM... | |||||||||||||
Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
